Shilpa Medicare jumps 9% on USFDA nod for Dimethyl Fumarate that used for multiple sclerosis patients

Dimethyl Fumarate delayed-release capsules is a generic of Tecfidera.

Shilpa Medicare shares spiked 8.75 percent intraday Friday after receiving tentative approval from the US health regulator for Dimethyl Fumarate delayed-release capsules.

Dimethyl Fumarate delayed-release capsules is a generic of Tecfidera.

Abbreviated new drug application (ANDA) for Dimethyl Fumarate delayed-release capsules in the strengths of 120 mg and 240 mg has been granted tentative approval by the United States Food and Drug Administration (USFDA), Shilpa Medicare said in a BSE filing.

 Share Market Tips

The drug is used for the treatment of relapsing forms of multiple sclerosis.

Quoting IQVIA MAT second quarter 2018 data, Shilpa Medicare said the US market for Dimethyl Fumarate delayed-release capsules is approximately $3.46 billion.

At 12:03 hours IST, the stock was quoting at Rs 393.85, up Rs 19.85, or 5.31 percent on the BSE.

Disclaimer:- The views and investment tips expressed by investment experts are their own. Ripples Advisory advises users to check with certified experts before taking any investment decisions.

Best Share Market News, Click Here To Get More News - Share Market Tips, for 2 Days Free Trial give a missed call @9644405056 and Get Share Market Services.

Comments

Popular posts from this blog

Daily equity Market By Ripplesadvisory Report 16-Aug-2016

सकारात्मक वैश्विक रुझानों के सहारे बाजार में मजबूती, निफ्टी 10,900 के ऊपर

11-year data suggests bears control D-Street in September; can bulls defy odds?